| scholarly article | Q13442814 |
| P2093 | author name string | H Chen | |
| Z Wu | |||
| A Pinter | |||
| S C Kayman | |||
| C Shotton | |||
| S A Tilley | |||
| J McKeating | |||
| K Revesz | |||
| W Honnen | |||
| S Vijh-Warrier | |||
| P2860 | cites work | Site-directed mutagenesis by overlap extension using the polymerase chain reaction | Q27860503 |
| Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells | Q28288205 | ||
| Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1 | Q28646731 | ||
| Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 | Q28646835 | ||
| Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 | Q33571605 | ||
| Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. | Q33685950 | ||
| Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein | Q33937274 | ||
| Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers | Q34151491 | ||
| Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 | Q34292765 | ||
| Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein | Q34301897 | ||
| Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains | Q36620087 | ||
| Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. | Q36649240 | ||
| Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions | Q36650881 | ||
| Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains | Q36653730 | ||
| Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 | Q36690500 | ||
| Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation | Q36783052 | ||
| Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1 | Q36828367 | ||
| The role of the V3 loop of gp120 in HIV infection. | Q37152307 | ||
| Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus | Q37375345 | ||
| Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein | Q37412527 | ||
| Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody | Q37603996 | ||
| Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. | Q39143639 | ||
| A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. | Q40038304 | ||
| Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody | Q40062738 | ||
| Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo | Q40308974 | ||
| HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex | Q41379235 | ||
| Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region | Q41516510 | ||
| An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection | Q41679452 | ||
| Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120 | Q42129803 | ||
| A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity | Q44119196 | ||
| Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients | Q44255828 | ||
| A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates | Q45790079 | ||
| Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction | Q45872593 | ||
| Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides. | Q55062424 | ||
| Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. | Q55242478 | ||
| Relation of phenotype evolution of HIV-1 to envelope V2 configuration | Q70739957 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glycosylation | Q898365 |
| P304 | page(s) | 2271-2278 | |
| P577 | publication date | 1995-04-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain | |
| P478 | volume | 69 |
| Q33980469 | A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression |
| Q27489000 | Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates |
| Q39577162 | Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities |
| Q34146374 | Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. |
| Q38631979 | Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. |
| Q36978861 | Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design |
| Q33809112 | Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. |
| Q33648180 | Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. |
| Q33796067 | Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domains |
| Q33851094 | Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate |
| Q27677941 | Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals |
| Q34555891 | Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity |
| Q27486537 | Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C |
| Q47566053 | Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates |
| Q40015450 | Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. |
| Q35893538 | Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation |
| Q39877884 | Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site |
| Q39875204 | Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein |
| Q33785035 | Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity |
| Q24529180 | Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation. |
| Q34338411 | Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage |
| Q28345448 | Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera |
| Q28728517 | Monoclonal antibodies to the V2 domain of MN-rgp120: fine mapping of epitopes and inhibition of α4β7 binding |
| Q35870879 | N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120 |
| Q43124783 | Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution |
| Q33614461 | Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites |
| Q33842989 | Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. |
| Q35635163 | Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection |
| Q39723388 | Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization |
| Q39594428 | Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. |
| Q35677448 | Several N-Glycans on the HIV Envelope Glycoprotein gp120 Preferentially Locate Near Disulphide Bridges and Are Required for Efficient Infectivity and Virus Transmission |
| Q37084521 | Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses |
| Q36884458 | Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies |
| Q39485924 | Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding |
| Q35196671 | Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design |
| Q39875133 | Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site |
| Q36157711 | Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine |
| Q33788792 | The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. |
| Q39881014 | The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex |
| Q39551618 | The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. |
| Q34583767 | Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio |
Search more.